Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

OTHER 99 INDUSTRY 27 NIH 8 OTHER_GOV 2 NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 9 Lymphoid 9 Myeloid 4 Other neoplasm 2 Sarcoma 1 Plasma cell 1 Genitourinary 1 Classical hematology 1 Breast 1

Conditions

Multiple Myeloma 1

Interventions

Dexamethasone 48 Bortezomib 22 Lenalidomide 20 Cyclophosphamide 20 daratumumab 18 Calcium Dobesilate 15 Melphalan 13 Thalidomide 12 carfilzomib 9 pomalidomide 7 Prednisone 7 dexamethasone acetate 6 dexamethasone 21-phosphate 6 auricularum 6 Peripheral Blood Stem Cell Transplantation 6 Doxorubicin 6 isatuximab 5 Filgrastim 5 Vincristine 4 Interferon-alpha 3 Etoposide 3 selinexor 2 sargramostim 2 ixazomib 2 elotuzumab 2 cobimetinib 2 belantamab mafodotin 2 Steroids 2 Stem Cell Transplantation 2 Radiotherapy 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

NETWORK × fludarabine × Plasma cell × Clear all

NCT05257083 2026-03-17

CARTITUDE-6

European Myeloma Network B.V.

Phase 3 Active not recruiting

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡